Long term improvement in insulin response with gliclazide treatment.
Blood glucose, plasma insulin and C-peptide concentrations were measured in response to a standard meal in eight Type 2 (non-insulin dependent) diabetic patients before and after treatment with gliclazide for 33 +/- 9 months. Compared with the pre-treatment values, blood glucose levels remained significantly lower (p less than 0.00001), while plasma insulin and C-peptide concentrations remained significantly higher (p less than 0.00001 and p less than 0.001 respectively) throughout the treatment period. In contrast to previous studies, these findings demonstrate that prolonged sulphonylurea treatment produces continued enhancement of B cell secretion.
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D002096:C-Peptide / Q000097:blood; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005907:Gliclazide / Q000627:therapeutic use*; D006801:Humans; D007328:Insulin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D013453:Sulfonylurea Compounds; D005907:Gliclazide